Education
About Us
Working with TipRanks
Follow Us
Anthera Pharmaceuticals (ANTH)
OTHER OTC:ANTH
ANTH Stock Chart & Stats
Day’s RangeN/A
52-Week Range― - ―
Previous CloseN/A
Volume475.00
Average Volume (3M)N/A
Market Cap
$2.62K
Enterprise Value$2.62K
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-44.44
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding26,179,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.09
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.04% Other Institutional Investors
99.96% Public Companies and
Individual Investors
ANTH FAQ
What was Anthera Pharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is Anthera Pharmaceuticals’s market cap?
Anthera Pharmaceuticals’s market cap is $2.62K.
When is Anthera Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Anthera Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Anthera Pharmaceuticals overvalued?
According to Wall Street analysts Anthera Pharmaceuticals’s price is currently Overvalued.
Does Anthera Pharmaceuticals pay dividends?
Anthera Pharmaceuticals does not currently pay dividends.
What is Anthera Pharmaceuticals’s EPS estimate?
Anthera Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Anthera Pharmaceuticals have?
Anthera Pharmaceuticals has 26,179,000 shares outstanding.
What happened to Anthera Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Anthera Pharmaceuticals?
Currently, no hedge funds are holding shares in ANTH
Company Description
Anthera Pharmaceuticals
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.
Biodexa Pharmaceuticals
―
Salarius Pharmaceuticals
―
Matinas BioPharma
―
Hepion Pharmaceuticals
―
Windtree Therapeutics
―